A new intravenous drug designed to treat a specific type of skin cancer has been approved for use in the United States, according to a March 23 announcement from its makers, Merck KGaA and Pfizer Inc.
Bavencio was designed to treat Merkel cell carcinoma, an unusual and aggressive form of skin cancer, according to Merkelcell.org, a consortium of physicians treating the condition.
The new medicine, developed by a collaboration of the two pharmaceutical giants, contains avelumab, a substance that fights the disease by enhancing a patient’s immune response.
Massachusetts-based EMD Serono, Merck’s U.S. and Canadian biopharmaceutical subsidiary, will market the drug, the release said.
Immunotherapy drug approved for U.S. patients
Organizations in this Story
Want to get notified whenever we write about Pfizer ?
Next time we write about Pfizer, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.Sign-up for Alerts